Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This paper presents a case of a young male with linear and annular lupus panniculitis of the scalp, detailing trichoscopic findings and their correlation with histopathological features, but reports no new generalizable results.

This review indicates that low-level laser therapy may stimulate hair growth in both men and women with androgenetic alopecia, showing similar efficacy to minoxidil in some studies, but requires more robust evidence.

This study found that the n-hexane fraction from Leea indica leaves significantly increased hair growth in mice and showed potential as a natural treatment for alopecia.

This study developed the Alopecia Areata Children's Quality of Life Index (AAcQLI) to assess quality of life in children with alopecia areata, demonstrating good reliability and validity in initial tests.

In this study, low-level light therapy using a new helmet-type device significantly increased hair density and thickness in patients with androgenetic alopecia, showing no adverse events or side effects, suggesting it may be a safe and effective treatment option for both sexes.

Alopecia areata is caused by immune system issues, and JAK inhibitors might help treat it.

This review suggested that low-level light therapy using red/near-infrared light could be a safe and effective treatment for various skin and hair conditions, though more robust trials are needed to solidify its clinical utility.

CCCA affects Black men too, with a genetic link found in the PADI3 gene.

This case study in an 8-month-old mixed-breed dog with symptoms and histopathological findings supports a diagnosis of hereditary junctional epidermolysis bullosa, although specific genetic mutations weren't identified.

JAK inhibitors are effective and generally safe for treating alopecia areata, but monitoring for side effects is important.

This study found that treatment with oral tofacitinib, alone or with other therapies, was associated with clinical improvement in most patients with recalcitrant lichen planopilaris.

This systematic review evaluated the safety of JAK-inhibitors for alopecia areata, finding that most adverse events were mild and systemic formulations were well-tolerated; however, increased rates of certain infections and laboratory abnormalities were noted, with isolated severe cases but no fatal outcomes.

In this case report, a female patient with Graham-Little-Piccardi-Lassueur Syndrome and hidradenitis suppurativa showed significant improvement in symptoms, including hair loss and lesions, after six months of treatment with tofacitinib, with no recurrence or adverse effects over a two-year follow-up.

This case series observed that five Black pediatric patients with moderate to severe alopecia areata showed significant hair regrowth and minimal disease activity after treatment with topical JAK inhibitors, vitamin D supplementation, and antihistamines, with additional therapies in some cases.

This study shows that in a mouse model of Alopecia Areata, selective JAK1 inhibition facilitated hair regrowth and inflammation resolution while potentially offering a better safety profile compared to pan-JAK inhibition.

Frontal fibrosing alopecia can occur with lichen planus pigmentosus, needing careful diagnosis and treatment.

This case report describes a 78-year-old male with adenocarcinoma and Hypertrichosis lanuginosa acquisita, highlighting the need to consider malignancy in patients with unexplained excessive hair growth.

This case report describes a 61-year-old Italian man with a rare, localized variant of junctional epidermolysis bullosa linked to the R795X mutation in the COL17A1 gene, highlighting the importance of precise diagnosis for effective management of rare genetic disorders.

This review examines the JAK/STAT signaling pathway's significance in inflammatory skin diseases and evaluates the efficacy and safety of oral and topical JAK inhibitors for treating vitiligo and alopecia areata. Results are not reported in this study.

In this open-label study, participants reported that the LustrivaTM BH-002 two-step system improved various aspects of hair, skin, and nail health and appearance after three months of use.

A man with both skin lesions and lung cancer improved quickly with chemotherapy, suggesting the skin condition might be a reaction to immune system injury.

This review discusses the unclear etiology and potential contributing factors of frontal fibrosing alopecia and reports no new clinical findings.

In this study, patients with alopecia areata displayed altered scalp microbiota compared to healthy controls, and treatment with JAK kinase inhibitors largely restored these microbial changes, providing insights into the potential role of the skin microbiome in alopecia areata.

This study observed that patients receiving IL-2 immunotherapy developed a skin eruption characterized by burning and pruritus, which resolved shortly after stopping the infusion, suggesting that IL-2 mediated these effects.

The researchers reported a case where treatment with tofacitinib improved both hair loss and skin lesions in a patient with Graham-Little-Piccardi-Lassueur Syndrome and hidradenitis suppurativa over six months, with no recurrence or adverse events during two-year follow-up.

This report describes three cases of hypertrichosis lanuginosa acquisita occurring after cytotoxic chemotherapy for cancer, suggesting a possible relationship which is discussed alongside a review of existing literature.

Using Janus kinase inhibitors (JAKi) in COVID-19 treatment requires careful consideration due to their immunosuppressive effects.

This study explored the potential of the lysate and lipoteichoic acid from Lactiplantibacillus plantarum APsulloc 331261 to improve scalp seborrheic dermatitis by modulating inflammatory and lipogenesis pathways in vitro, suggesting potential as a natural treatment option.